Psychopharmacology

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

Sara Robinson, DNP, RN, PMHNP-BC, provides insight on considerations surrounding prescribing psychiatric medications for perinatal patients.

Rebecca Barbee, PA-C, shares tips on addressing the heat wave and its implications when talking with patients.

Learn more about how to best assess and treat tardive dyskinesia.

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

In response to the threats associated with "DIY psychiatry," experts call for a renewed focus on collaboration and shared decision-making.

Deprescribing: a critical practice in medicine, emphasizing thoughtful medication management and patient-centered care for optimal health outcomes.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?